Skip to main content
TipRanks
Go Ultimate75% OFF

Mountain Valley MD (MLCO) AI Stock Analysis

56 Followers
TSE:MLCO

Mountain Valley MD

(CNQX:MLCO)

Select Model
Rating:42Neutral
Price Target:CAD 0.05â–²(6.67% Upside)
Action:reiterated
Date:10/23/26

The overall score of 42 reflects a high-risk, pre-revenue biotechnology company in financial distress. The most significant factor is the precarious financial performance, characterized by a rapid cash burn rate and minimal revenue that is vastly outpaced by operating losses. This is compounded by a persistently bearish technical trend, with the stock price trading below all major moving averages, indicating strong negative market momentum. The negative P/E ratio further confirms the lack of current earnings power. The company's survival is contingent on securing additional financing or achieving a dramatic, and currently unproven, revenue ramp.

Positive Factors
Low reported debtZero reported TTM debt reduces direct interest and refinancing pressure, giving the company more balance-sheet flexibility than a similarly unprofitable business with significant leverage. This can preserve strategic options if operating performance improves or additional funding is required.
Negative Factors
Persistent cash burnDeeply negative operating and free cash flow show that the business is not self-funding and that reported losses are translating into substantial cash outflows. Continued burn can constrain product development, increase reliance on external financing, and weaken resilience if funding conditions deteriorate.

Mountain Valley MD (MLCO) vs. iShares MSCI Canada ETF (EWC)

-100%0%100%200%300%400%500%TSE:MLCO+200.00%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 20.57M
Dividend Yield
―
Average Volume (3M)
117.65K
Price to Earnings (P/E)
-4.6
Beta (1Y)
-0.69
Revenue Growth
48.94%
EPS Growth
53.81%
Country
Canada
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Mountain Valley MD Business Overview & Revenue Model

Company Description

The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksomeâ„¢ and Quicksolâ„¢. The Quicksomeâ„¢ patented technology utilizes prop...

Mountain Valley MD Financial Statement Overview

Summary

Financial health is precarious. The company has minimal revenue ($70k TTM) and deep net losses (-$3.7M TTM). The balance sheet is debt-free but assets have shrunk to $1.84M from $8.97M, and the cash burn rate is severe with -$2.2M in operating cash flow. The recent capital raise provides a temporary lifeline but does not resolve the fundamental lack of profitability.

Income Statement

18Very Negative

Balance Sheet

35Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue65.00K65.00K49.00K60.00K0110.00K
Gross Profit37.00K-2,00049.00K-346.00K-446.00K70.00K
EBITDA-2.26M-2.27M-3.16M-2.78M-6.89M-9.29M
Net Income-2.79M-2.79M-7.47M-7.67M-7.44M-9.71M
Balance Sheet
Total Assets524.00K524.00K2.74M8.97M16.77M25.27M
Cash, Cash Equivalents and Short-Term Investments334.00K334.00K1.72M5.92M9.71M14.22M
Total Debt403.00K403.00K006,00044.00K
Total Liabilities665.00K665.00K209.00K258.00K591.00K422.00K
Stockholders Equity-141.00K-141.00K2.53M8.71M16.18M24.85M
Cash Flow
Free Cash Flow-2.12M-2.12M-3.91M-3.80M-4.85M-5.68M
Operating Cash Flow-2.11M-2.11M-3.90M-3.30M-4.79M-5.59M
Investing Cash Flow200.00K200.00K-290.00K-503.00K1.89M-98.00K
Financing Cash Flow519.00K519.00K0-6,000-1.60M395.00K

Mountain Valley MD Technical Analysis

Technical Analysis SentimentNegative
Last Price0.04

Price Trends

50DMA0.05Negative
100DMA0.07Negative
200DMA0.06Negative

Market Momentum

MACD-0.00Positive
RSI40.81Neutral
STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MLCO, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.81 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MLCO.

Mountain Valley MD Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:MLCO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:LOBETSE:LOBE43NeutralCAD 15.41M-2.43-338.76%――31.00%
TSE:MLCOTSE:MLCO42NeutralCAD 20.57M-4.64-443.11%―48.94%53.81%
TSE:PCLOTSE:PCLO39UnderperformCAD 8.41M-2.4128.59%―0.90%57.73%
TSE:RVVTSE:RVV39UnderperformCAD 6.67M-12.5026.78%――90.84%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%TSE:MLCOTSE:RVVTSE:PCLOTSE:LOBEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:MLCO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:MLCOMountain Valley Md Holdings Inc0.040.03200.00%
TSE:RVVRevive Therapeutics0.010.0050.00%
TSE:PCLOPharmacielo0.040.000.00%
TSE:LOBELobe Sciences Ltd0.050.0111.11%

Mountain Valley MD Corporate Events

Business Operations and StrategyProduct-Related Announcements

More Life Company’s Quicksome Study Shows Rapid Sublingual Testosterone Delivery

Positive
Oct 7, 2026

The More Life Company reported results from an exploratory human pharmacokinetic study of its Quicksome sublingual delivery technology using USP-grade testosterone. In an eight-participant trial, 5 mg and 15 mg Quicksome tablets produced substantial...

Business Operations and StrategyProduct-Related Announcements

The More Life Company Moves to U.S. Commercialization for Quicksome Compounded Drugs

Positive
Oct 7, 2026

The More Life Company Corp. has signed a strategic letter of intent with an established U.S. 503A compounding pharmacy to develop, compound and commercialize Quicksomeâ„¢-enabled prescription compounded pharmaceuticals in the United States. The contemp...

Business Operations and StrategyDelistings and Listing Changes

The More Life Company Updates U.S. and Canadian Trading Symbols After Rebrand

Positive
Aug 21, 2026

The More Life Company Corp., formerly Mountain Valley MD Holdings Inc., operates in the life sciences sector with a focus on technologies that enhance crop productivity and resilience and improve the formulation, stability and delivery of active ingr...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026